{
    "organizations": [],
    "uuid": "64f2d0894f0ae59b1554d8aac46287e04bb03494",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/29/pr-newswire-biondvax-announces-first-quarter-2018-financial-results.html",
    "ord_in_thread": 0,
    "title": "BiondVax Announces First Quarter 2018 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NESS ZIONA, Israel, May 29, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended March 31, 2018.\nFirst Quarter 2018 Financial Summary\nResults are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.514 (NIS/$US) as at March 29, 2018\nFirst quarter operating expenses were NIS 12.6m ($3.6m) compared with NIS 2.97m for the first quarter of 2017; First quarter R&D expenses amounted to NIS 11.7m ($3.3m) compared with NIS 1.87m for the first quarter of 2017;\nAs of March 31, 2018, BiondVax had cash and cash equivalents of NIS 55.7 million ($15.8 million) as compared to NIS 71.3 million as of December 31, 2017. The decrease is attributable to execution of planned ongoing operations related to launch of the pivotal, clinical efficacy, Phase 3 trial of the Company's M-001 Universal Flu Vaccine candidate, and construction of a mid-size commercial manufacturing facility.\nAbout BiondVax\nBiondVax (Nasdaq: BVXV) is an advanced clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit www.biondvax.com .\nForward Looking Statements\nThis press release contains within the meaning of the Private Litigation Reform Act of 1995. Words such as \"expect,\" \"believe,\" \"intend,\" \"plan,\" \"continue,\" \"may,\" \"will,\" \"anticipate,\" and similar expressions are intended to identify . These involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results of Phase 2 & 3 trials, delays or obstacles in launching and/or successfully completing our clinical trials, the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading \"Risk Factors\" in our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov , and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.We undertake no obligation to revise or update any forward-looking statement for any reason.\n** Tables to Follow **\nBALANCE SHEETS\nIn thousands, except per share data\n*) Represents an amount lower than NIS 1.\nConvenience\ntranslation\nDecember 31,\nMarch 31,\nMarch 31,\n2017\n2017\n2018\n2018\nAudited\nUnaudited\nUnaudited\nN I S\nU.S. dollars\nCURRENT ASSETS:\nCash and cash equivalents\n71,382\n24,020\n55,675\n15,844\nMarketable securities\n-\n4,068\n-\nShort-term deposits\n-\n6,751\n-\n-\nOther receivables\n3,923\n4,979\n2,975\n847\n75,305\n39,818\n58,650\n16,691\nLONG‑TERM ASSETS:\nProperty, plant and equipment\n5,510\n1,297\n12,537\n3,568\nOther long term assets\n880\n478\n880\n250\n6,390\n1,775\n13,417\n3,818\n81,695\n41,593\n72,067\n20,509\nCURRENT LIABILITIES:\nTrade payables\n6,223\n752\n8,526\n2,426\nOther payables\n660\n526\n768\n219\n6,883\n1,278\n9,294\n2,645\nLONG‑TERM LIABILITIES:\nLiability in respect of government grants\n10,300\n11,252\n3,202\nWarrants\n8,177\n10,848\n9,315\n2,651\nSeverance pay liability, net\n83\n76\n78\n22\n18,560\n10,924\n20,645\n5,875\nSHAREHOLDERS' EQUITY:\nOrdinary shares of NIS 0. 1 par value:\nAuthorized: 391,000,000 shares as of March\n31, 2018, 2017 (unaudited) and\nDecember 31, 2016; Issued and\nOutstanding: 261,419,599 , 162,481,153\nand 261,419,599 shares respectively\n*) -\n*) -\n*) -\n*) -\nShare premium\n179,669\n129,550\n179,747\n51,152\nOptions\n-\n533\n-\n-\nOther comprehensive income\n-\n6\n-\nAccumulated deficit\n(123,417)\n(100,698)\n(137,619)\n(39,163)\n56,252\n29,391\n42,128\n11,989\n81,695\n41,593\n72,067\n20,509\nSTATEMENTS OF COMPREHENSIVE INCOME\nIn thousands, except per share data\nConvenience\ntranslation\nThree months\nYear ended\nThree months ended\nended\nDecember 31,\nMarch 31,\nMarch 31,\n2017\n2017\n2018\n2018\nAudited\nUnaudited\nUnaudited\nNIS\nU.S. dollars\nOperating expenses:\nResearch and development, net of\nparticipations\n18,777\n1,874\n11,745\n3,342\nMarketing, general and administrative\n4,879\n1,094\n884\n251\nTotal operating expenses\n23,656\n2,968\n12,629\n3,593\nOperating loss\n(23,656)\n(2,968)\n(12,629)\n(3,593)\nFinancial income\n18\n8\n-\n-\nFinancial expense\n(10,913)\n(8,872)\n(1,573)\n(448)\nNet loss\n(34,551)\n(11,832)\n(14,202)\n(4,041)\nOther comprehensive loss:\nLoss from available-for-sale marketable securities\n(6)\n-\n-\n-\nTotal comprehensive loss\n(34,557)\n(11,832)\n(14,202)\n(4,041)\nBasic and Diluted net loss per share\n(0.17)\n(0.07)\n(0.05)\n(0.02)\nWeighted average number of shares\noutstanding used to compute basic and\ndiluted loss per share\n201,030,768\n162,481,153\n261,419,599\n261,419,599\nContact Details\nJoshua Phillipson\n+972 8 930 2529\nj.phillipson@biondvax.com\nView original content: http://www.prnewswire.com/news-releases/biondvax-announces-first-quarter-2018-financial-results-300655630.html\nSOURCE BiondVax Pharmaceuticals Ltd.",
    "published": "2018-05-29T15:00:00.000+03:00",
    "crawled": "2018-05-29T16:29:57.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "ness",
        "ziona",
        "israel",
        "may",
        "biondvax",
        "pharmaceutical",
        "nasdaq",
        "bvxv",
        "clinical",
        "stage",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "commercializing",
        "universal",
        "flu",
        "vaccine",
        "candidate",
        "today",
        "announced",
        "financial",
        "result",
        "quarter",
        "ended",
        "march",
        "first",
        "quarter",
        "financial",
        "summary",
        "result",
        "new",
        "israel",
        "shekel",
        "ni",
        "convenience",
        "translation",
        "u",
        "provided",
        "using",
        "exchange",
        "rate",
        "u",
        "march",
        "first",
        "quarter",
        "operating",
        "expense",
        "ni",
        "compared",
        "ni",
        "first",
        "quarter",
        "first",
        "quarter",
        "r",
        "expense",
        "amounted",
        "ni",
        "compared",
        "ni",
        "first",
        "quarter",
        "march",
        "biondvax",
        "cash",
        "cash",
        "equivalent",
        "ni",
        "million",
        "million",
        "compared",
        "ni",
        "million",
        "december",
        "decrease",
        "attributable",
        "execution",
        "planned",
        "ongoing",
        "operation",
        "related",
        "launch",
        "pivotal",
        "clinical",
        "efficacy",
        "phase",
        "trial",
        "company",
        "universal",
        "flu",
        "vaccine",
        "candidate",
        "construction",
        "commercial",
        "manufacturing",
        "facility",
        "biondvax",
        "biondvax",
        "nasdaq",
        "bvxv",
        "advanced",
        "clinical",
        "stage",
        "biopharmaceutical",
        "company",
        "developing",
        "universal",
        "flu",
        "vaccine",
        "vaccine",
        "candidate",
        "called",
        "designed",
        "provide",
        "protection",
        "current",
        "future",
        "seasonal",
        "pandemic",
        "influenza",
        "virus",
        "strain",
        "biondvax",
        "proprietary",
        "technology",
        "utilizes",
        "unique",
        "combination",
        "conserved",
        "common",
        "influenza",
        "virus",
        "peptide",
        "activating",
        "arm",
        "immune",
        "system",
        "effect",
        "total",
        "completed",
        "phase",
        "phase",
        "human",
        "clinical",
        "trial",
        "covering",
        "participant",
        "vaccine",
        "shown",
        "safe",
        "immunogenic",
        "please",
        "visit",
        "forward",
        "looking",
        "statement",
        "press",
        "release",
        "contains",
        "within",
        "meaning",
        "private",
        "litigation",
        "reform",
        "act",
        "word",
        "expect",
        "believe",
        "intend",
        "plan",
        "continue",
        "may",
        "anticipate",
        "similar",
        "expression",
        "intended",
        "identify",
        "involve",
        "certain",
        "risk",
        "uncertainty",
        "reflect",
        "management",
        "current",
        "view",
        "respect",
        "certain",
        "current",
        "future",
        "event",
        "subject",
        "various",
        "risk",
        "uncertainty",
        "assumption",
        "could",
        "cause",
        "result",
        "expected",
        "management",
        "biondvax",
        "pharmaceutical",
        "risk",
        "uncertainty",
        "include",
        "limited",
        "risk",
        "drug",
        "development",
        "involves",
        "lengthy",
        "expensive",
        "process",
        "uncertain",
        "outcome",
        "result",
        "phase",
        "trial",
        "delay",
        "obstacle",
        "launching",
        "successfully",
        "completing",
        "clinical",
        "trial",
        "impact",
        "global",
        "economic",
        "environment",
        "company",
        "customer",
        "target",
        "base",
        "adequacy",
        "available",
        "cash",
        "resource",
        "ability",
        "raise",
        "capital",
        "needed",
        "detailed",
        "information",
        "risk",
        "uncertainty",
        "affecting",
        "company",
        "contained",
        "heading",
        "risk",
        "factor",
        "annual",
        "report",
        "form",
        "year",
        "ended",
        "december",
        "filed",
        "security",
        "exchange",
        "commission",
        "sec",
        "available",
        "sec",
        "website",
        "company",
        "periodic",
        "filing",
        "sec",
        "stock",
        "undertake",
        "obligation",
        "revise",
        "update",
        "statement",
        "reason",
        "table",
        "follow",
        "balance",
        "sheet",
        "thousand",
        "except",
        "per",
        "share",
        "data",
        "represents",
        "amount",
        "lower",
        "ni",
        "convenience",
        "translation",
        "december",
        "march",
        "march",
        "audited",
        "unaudited",
        "unaudited",
        "n",
        "dollar",
        "current",
        "asset",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "deposit",
        "receivables",
        "asset",
        "property",
        "plant",
        "equipment",
        "long",
        "term",
        "asset",
        "current",
        "liability",
        "trade",
        "payable",
        "payable",
        "liability",
        "liability",
        "respect",
        "government",
        "grant",
        "warrant",
        "severance",
        "pay",
        "liability",
        "net",
        "shareholder",
        "equity",
        "ordinary",
        "share",
        "ni",
        "par",
        "value",
        "authorized",
        "share",
        "march",
        "unaudited",
        "december",
        "issued",
        "outstanding",
        "share",
        "respectively",
        "share",
        "premium",
        "option",
        "comprehensive",
        "income",
        "accumulated",
        "deficit",
        "statement",
        "comprehensive",
        "income",
        "thousand",
        "except",
        "per",
        "share",
        "data",
        "convenience",
        "translation",
        "three",
        "month",
        "year",
        "ended",
        "three",
        "month",
        "ended",
        "ended",
        "december",
        "march",
        "march",
        "audited",
        "unaudited",
        "unaudited",
        "ni",
        "dollar",
        "operating",
        "expense",
        "research",
        "development",
        "net",
        "participation",
        "marketing",
        "general",
        "administrative",
        "total",
        "operating",
        "expense",
        "operating",
        "loss",
        "financial",
        "income",
        "financial",
        "expense",
        "net",
        "loss",
        "comprehensive",
        "loss",
        "loss",
        "marketable",
        "security",
        "total",
        "comprehensive",
        "loss",
        "basic",
        "diluted",
        "net",
        "loss",
        "per",
        "share",
        "weighted",
        "average",
        "number",
        "share",
        "outstanding",
        "used",
        "compute",
        "basic",
        "diluted",
        "loss",
        "per",
        "share",
        "contact",
        "detail",
        "joshua",
        "phillipson",
        "view",
        "original",
        "content",
        "http",
        "source",
        "biondvax",
        "pharmaceutical",
        "ltd"
    ]
}